announced today that the Central Drugs Standard Control Organisation (CDSCO) in India has approved Afrezza (insulin human) Inhalation Powder in adults. The CDSCO decision follows existing ...

New Delhi: India is set to see the launch of Afrezza—the only rapid-acting, inhaled insulin to help control high blood sugar in adults with type 1 or type 2 diabetes—ten years after the ...

announced today that the Central Drugs Standard Control Organisation (CDSCO) in India has approved Afrezza (insulin human) Inhalation Powder in adults. The CDSCO decision follows existing approvals in ...

announced today that the Central Drugs Standard Control Organisation (CDSCO) in India has approved Afrezza (insulin human) Inhalation Powder in adults. The CDSCO decision follows existing approvals in ...

MannKind Corporation announced today that it plans to meet with the FDA to discuss a potential supplemental new drug application (sNDA) for its inhaled insulin product, Afrezza, following positive ...

(RTTNews) - MannKind Corporation (MNKD) Monday reported positive six-month results from its Phase 3 INHALE-1 study of Afrezza Inhalation Powder, a rapid-acting inhaled human insulin, in ...

Medscape Medical News, June 27, 2024 ADA 2024 Inhaled Insulin Plus Degludec an Option for Type 1 Diabetes Use of premeal Afrezza insulin plus long-acting degludec insulin was non-inferior to ...

Dec. 16, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with ...